Equities

Xenetic Biosciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
XBIO:NAQ

Xenetic Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.17
  • Today's Change-0.216 / -9.04%
  • Shares traded39.46k
  • 1 Year change-48.18%
  • Beta2.2945
Data delayed at least 15 minutes, as of Feb 13 2026 20:59 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.

  • Revenue in USD (TTM)2.86m
  • Net income in USD-3.16m
  • Incorporated2011
  • Employees2.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cannabis Bioscience Internatnl Hlgs Inc148.34k-555.16k4.65m2.00------31.35-0.00006-0.000060.00001-0.00014.55--11.3574,170.00-1,702.42-652.66----73.1187.76-374.25-177.59---4.30----21.770.866215.74------
Genprex Inc0.00-17.05m4.68m15.00--2.64-----52.85-52.850.000.76460.00----0.00-448.99-100.44-1,253.41-109.71------------0.00------30.69------
Decoy Therapeutics Inc0.00-5.00m4.72m2.00--0.1643-----39.19-39.190.004.500.00----0.00-100.54-73.17-139.55-84.56-------987.44----0.00------55.55------
Bio Green Med Solution Inc81.00k-6.97m4.81m12.00--0.4835--59.32-80.13-80.130.07752.030.012--0.0821---80.35-65.34-175.85-83.8520.99---6,714.82-17,774.735.07-241.390.00---89.76--50.73------
Bioxytran Inc0.00-2.11m4.81m2.00---------0.0235-0.02350.00-0.03260.00-------1,340.44-1,468.56---------------1.99--------47.08------
Cyclerion Therapeutics Inc2.86m-2.20m4.91m1.00--0.4843--1.72-0.7587-0.75871.002.580.2957--39.652,855,000.00-22.77-53.70-24.80-63.57-----77.02-1,913.83----0.00-----15.0075.72------
Aspire Biopharma Holdings Inc1.94k-28.70m4.95m--------2,551.26-65.96-65.960.0022-9.260.0004-------633.21------45.36---1,479,598.00--0.1708-6.20---------380.85------
Weed Inc0.00-755.25k4.96m2.00---------0.0058-0.00580.00-0.00380.00----0.00-133.78-117.17---371.94-----------22.55---------1,518.25------
Silexion Therapeutics Corp0.00-9.25m4.97m11.00--0.7125-----25.21-25.210.002.230.00----0.00-125.80---221.96-------------84.500.1808-------223.39------
Xenetic Biosciences Inc2.86m-3.16m4.98m2.00--0.8478--1.74-2.05-2.051.852.570.436----1,429,470.00-48.14-42.99-57.42-46.44-----110.40-373.71----0.00---1.56171.114.22------
Acurx Pharmaceuticals Inc0.00-9.17m5.02m4.00--0.9751-----8.54-8.540.002.020.00----0.00-151.72-158.12-291.07-208.61------------0.00------3.26------
Processa Pharmaceuticals Inc0.00-12.93m5.03m10.00--0.8047-----35.00-35.000.002.760.00----0.00-206.50-104.23-270.68-112.35------------0.00-------6.55------
BioNexus Gene Lab Corp9.47m-2.30m5.06m30.00--0.5641--0.5345-1.28-1.285.273.791.026.736.42---24.68-6.00-27.80-7.7514.7714.31-24.27-4.986.81-1,354.050.00---2.66137.0939.20--77.67--
VivoSim Labs Inc140.00k-1.98m5.22m5.00--0.7383--37.26-0.1898-0.18980.0682.710.017--4.5910,769.23-24.12-51.63-34.26-56.4798.57---1,416.43-2,952.99----0.00--32.11-42.0183.04------
Bullfrog AI Holdings Inc116.67k-6.76m5.25m9.00--2.47--45.01-0.6936-0.69360.01190.18660.0319----12,963.33-184.34---233.50--18.76---5,770.66------0.0278---100.00---31.42------
MetaVia Inc0.00-16.22m5.26m9.00--0.5703-----13.88-13.880.002.880.00----0.00-87.87-99.54-167.49-140.07------------0.00-------121.27---48.18--
Data as of Feb 13 2026. Currency figures normalised to Xenetic Biosciences Inc's reporting currency: US Dollar USD

Institutional shareholders

9.16%Per cent of shares held by top holders
HolderShares% Held
Renaissance Technologies LLCas of 31 Dec 2025178.51k7.79%
DRW Securities LLCas of 31 Dec 202513.82k0.60%
Geode Capital Management LLCas of 31 Dec 202513.58k0.59%
JTC Plc /Private Banking/as of 31 Dec 20252.70k0.12%
Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 20251.24k0.05%
Alexis Investment Partners LLCas of 31 Dec 202525.000.00%
Bank of America, NA (Private Banking)as of 30 Sep 202511.000.00%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 20253.000.00%
Darwin Wealth Management LLCas of 31 Dec 20252.000.00%
BofA Securities, Inc.as of 30 Sep 20251.000.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.